Satt IDF Innov has licenced research at Institut Cochin and Institut Pierre-Louis to SkinDemic, which will now commercialise a treatment for acne and Kaposi's sarcoma.

Yale spinout Arvinas has added cash to its coffers as it prepares oncological treatments for forms of prostate and breast cancer.

TU Wien spinout Cogvis has developed a contactless sensor that predicts when a person might fall and is aimed at the elderly care sector.

UC Investment Office, an existing Constellation backer, has returned to contribute to a $100m round that took its total equity funding to $229m.

Access Industries contributed to a round that lifted the bone marrow transplant drug developer's overall funding to $150m.

Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.

The age-related disease drug developer, which counts Mayo Clinic and WuXi PharmaTech as investors, raised $55m as recently as last month.

Parkwalk has invested in the spinout through both its Parkwalk Opportunities Fund and the University of Oxford Innovation Fund IV.

The immunomodulation therapy developer has been backed by Pablo Legorreta in the wake of a phase 2 trial of its therapy for organ transplant patients.